Phase I/II Study of Avelumab in Pediatric Cancer Participants

Stopped Based on the limited activity observed with avelumab monotherapy in the pediatric population, the Phase II study part was cancelled.

Conditions

• Refractory or Relapsed Solid Tumors
• Lymphoma

Interventions

• DRUG: Avelumab
• DRUG: Avelumab

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]